cannabis penny stocks

1. Cannabis Science Inc Stock News Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs. Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

2. At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

3. Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional. Some applications of cannabinoids have been well established in peer-reviewed literature such as alleviating nausea and stimulating the appetite for people with AIDS and Cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its perceived effectiveness in alleviating certain autoimmune disorders, such as Crohn’s Disease. Our team of scientists will produce and commercialize products derived from cannabis-based botanical extracts. Even today, new uses for cannabinoids are consistently discovered. For example, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments. Cannabis Penny Stocks

4. In 2001, an article published in the Canadian Medical Association Journal revealed that, based on self-identified needs, it is estimated that 2% (or 400,000) of Canadian adults were already utilizing cannabinoids for medical purposes. With ever increasing use and scientific support for cannabinoid medicines occurring in the US and around the world, we are looking at a new multi-billion dollar industry that will play a dramatic role that will impact human health on a global scale. We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements. Cannabis Penny Stocks

5. CBIS Sets the Stage for High-Growth Amidst DEA Historical National Industry Changes for Critical Ailment Treatments & Historic California Voting in November LOS ANGELES, CA--(Marketwired - Jun 30, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the relocation of their corporate headquarters to Irvine, California. The company's HQ move to California will put them in closer proximity to its vital laboratory resources, key distributors, and many patients. This move will help the company cut costs, decrease time to market for new products, and perform clinical trials more efficiently with a new California laboratory, clinical trials unit, and medical treatment facility to be announced shortly. CBIS looks to target the high growth projected in the national industry changes, such as the possible DEA reclassification of cannabis which can positively multiply the efforts of the Company's scientific team dramatically, and the Historic California voting in November. These changes can open the markets dramatically for the Company's proprietary cannabinoid formulations being created to be distributed nationwide. The urgent objective is the treatment of critical ailments, such as, various Cancers, HIV/AIDS, Pain Management, Autism, PTSD, and other neurological conditions. Though this list represents only a handful of the targeted ailments we hope to treat, it reflects some of the serious medical afflictions we are dealing with. Cannabis Science Inc Stock News

6. The Company fully understands that while the price is high, one blockbuster pharmaceutical drug can change the framework forever in Cannabis Science, and the Company believes it has more than one. While the Company negotiates to close a new deal with its North California property partners it continues forward with creating lab expansions for IGXBio'sGenePro FDA Investigational New Drug (IND) Number 015982 for further drug development to identify & develop agonist cannabinoids for GenePro, closing large educational & cultivation property development deals utilizing the strengths of Universities. We feel empowered and strengthened with clinical drug development confidence as GW Pharma announces positive results with its CBD-Based Epilepsy formulation while mapping out its own critical ailment drug development plans for many critical ailments based on successful self-medicating cannabinoid cancer treatments and other amplified results. Cannabis Science Inc Stock News

7. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders. Cannabis Science Inc Stock

8. Cannabis Science is one of the longest standing companies in the cannabis business. We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime. Cannabis Science Inc Stock

9. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. Cannabis Science Inc Stock Cannabis Science, Inc. is a patient oriented company dedicated to meeting the needs of the community with products based on cannabinoid science, as well as being an advocate for patient rights throughout the world.

10. Cannabis Science Inc Stock News www.cannabisscience.com For more information visit our website